Drug Profile
Research programme: cardiology diagnostics - BTG
Alternative Names: BGC-C2I molecular imaging probe; Cardiology diagnostics research programme - BTGLatest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator BTG
- Class Radiopharmaceutical diagnostics
- Mechanism of Action Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Coronary artery disease
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 07 May 2007 No development reported - Preclinical for Coronary artery disease (diagnosis) in USA (unspecified route)
- 01 Mar 2004 The programme is available for licensing in in Europe and North America (http://www.btgplc.com)